Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jennifer M Giltnane

Showing results (1-10 of 39) with videos related to

Pageof 4
Sort By:
Discovery Medicine|June 3, 2014
Rationale for targeting the Ras/MAPK pathway in triple-negative breast cancerJennifer M Giltnane, Justin M Balko
Methods in Molecular Biology (Clifton, N.J.)|April 22, 2009
Quantitative, fluorescence-based in-situ assessment of protein expressionChristopher B Moeder, Jennifer M Giltnane, Sharon Pozner Moulis, et al.
Cancer|March 31, 2009
Quantitative multiplexed analysis of ErbB family coexpression for primary breast cancer prognosis in a large retrospective cohortJennifer M Giltnane, Christopher B Moeder, Robert L Camp, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 20, 2007
Quantitative measurement of epidermal growth factor receptor is a negative predictive factor for tamoxifen response in hormone receptor positive premenopausal breast cancerJennifer M Giltnane, Lisa Rydén, Melissa Cregger, et al.
Archives of Pathology & Laboratory Medicine|October 7, 2008
Comparison of quantitative immunofluorescence with conventional methods for HER2/neu testing with respect to response to trastuzumab therapy in metastatic breast cancerJennifer M Giltnane, Annette Molinaro, Huan Cheng, et al.
Cancer Research|April 6, 2007
High HSP90 expression is associated with decreased survival in breast cancerElah Pick, Yuval Kluger, Jennifer M Giltnane, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 15, 2007
Bimodal population or pathologist artifact?David L Rimm, Jennifer M Giltnane, Christopher Moeder, et al.
Breast Cancer Research : BCR|April 24, 2008
Expression patterns and prognostic value of Bag-1 and Bcl-2 in breast cancerYasmine Nadler, Robert L Camp, Jennifer M Giltnane, et al.
Molecular Cancer|June 17, 2010
The ERalpha coactivator, HER4/4ICD, regulates progesterone receptor expression in normal and malignant breast epitheliumJerzy Rokicki, Partha M Das, Jennifer M Giltnane, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 2007
Quantitative justification of the change from 10% to 30% for human epidermal growth factor receptor 2 scoring in the American Society of Clinical Oncology/College of American Pathologists guidelines: tumor heterogeneity in breast cancer and its implications for tissue microarray based assessment of outcomeChristopher B Moeder, Jennifer M Giltnane, Malini Harigopal, et al.
Pageof 4

Showing results (1-10 of 39) with videos related to

Sort By:
Pageof 4
Discovery Medicine|June 3, 2014
Rationale for targeting the Ras/MAPK pathway in triple-negative breast cancerJennifer M Giltnane, Justin M Balko
Methods in Molecular Biology (Clifton, N.J.)|April 22, 2009
Quantitative, fluorescence-based in-situ assessment of protein expressionChristopher B Moeder, Jennifer M Giltnane, Sharon Pozner Moulis, et al.
Cancer|March 31, 2009
Quantitative multiplexed analysis of ErbB family coexpression for primary breast cancer prognosis in a large retrospective cohortJennifer M Giltnane, Christopher B Moeder, Robert L Camp, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 20, 2007
Quantitative measurement of epidermal growth factor receptor is a negative predictive factor for tamoxifen response in hormone receptor positive premenopausal breast cancerJennifer M Giltnane, Lisa Rydén, Melissa Cregger, et al.
Archives of Pathology & Laboratory Medicine|October 7, 2008
Comparison of quantitative immunofluorescence with conventional methods for HER2/neu testing with respect to response to trastuzumab therapy in metastatic breast cancerJennifer M Giltnane, Annette Molinaro, Huan Cheng, et al.
Cancer Research|April 6, 2007
High HSP90 expression is associated with decreased survival in breast cancerElah Pick, Yuval Kluger, Jennifer M Giltnane, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 15, 2007
Bimodal population or pathologist artifact?David L Rimm, Jennifer M Giltnane, Christopher Moeder, et al.
Breast Cancer Research : BCR|April 24, 2008
Expression patterns and prognostic value of Bag-1 and Bcl-2 in breast cancerYasmine Nadler, Robert L Camp, Jennifer M Giltnane, et al.
Molecular Cancer|June 17, 2010
The ERalpha coactivator, HER4/4ICD, regulates progesterone receptor expression in normal and malignant breast epitheliumJerzy Rokicki, Partha M Das, Jennifer M Giltnane, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 2007
Quantitative justification of the change from 10% to 30% for human epidermal growth factor receptor 2 scoring in the American Society of Clinical Oncology/College of American Pathologists guidelines: tumor heterogeneity in breast cancer and its implications for tissue microarray based assessment of outcomeChristopher B Moeder, Jennifer M Giltnane, Malini Harigopal, et al.
Pageof 4